Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other Non Operating Income: 2010-2025

Historic Other Non Operating Income for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to $219,000.

  • Lineage Cell Therapeutics' Other Non Operating Income fell 51.12% to $219,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 32.23%. This contributed to the annual value of -$670,000 for FY2024, which is 23.16% down from last year.
  • As of Q3 2025, Lineage Cell Therapeutics' Other Non Operating Income stood at $219,000, which was down 86.95% from $1.7 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Other Non Operating Income high stood at $1.7 million for Q2 2025, and its period low was -$2.5 million during Q3 2021.
  • Its 3-year average for Other Non Operating Income is $41,091, with a median of -$354,000 in 2024.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first crashed by 295.05% in 2022, then surged by 543.92% in 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Other Non Operating Income (Quarterly) stood at -$1.7 million in 2021, then surged by 123.72% to $398,000 in 2022, then surged by 214.57% to $1.3 million in 2023, then tumbled by 130.83% to -$386,000 in 2024, then tumbled by 51.12% to $219,000 in 2025.
  • Its Other Non Operating Income stands at $219,000 for Q3 2025, versus $1.7 million for Q2 2025 and -$231,000 for Q1 2025.